Aptevo Therapeutics (APVO) Earning Somewhat Positive Press Coverage, Study Shows

News stories about Aptevo Therapeutics (NASDAQ:APVO) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aptevo Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.1240632869406 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. Piper Jaffray Companies reissued an “overweight” rating and issued a $6.00 price target on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.

Shares of Aptevo Therapeutics (NASDAQ APVO) opened at $4.18 on Monday. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.50. The company has a quick ratio of 7.67, a current ratio of 7.76 and a debt-to-equity ratio of 0.19.

In related news, VP Randy Joe Maddux purchased 25,000 shares of Aptevo Therapeutics stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of $2.76 per share, with a total value of $69,000.00. Following the completion of the transaction, the vice president now directly owns 25,000 shares in the company, valued at $69,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.60% of the stock is owned by insiders.

WARNING: “Aptevo Therapeutics (APVO) Earning Somewhat Positive Press Coverage, Study Shows” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/25/aptevo-therapeutics-apvo-earning-somewhat-positive-press-coverage-study-shows.html.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Insider Buying and Selling by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit